Get the Stockscreener App
9.21
2.56%
0.23
Pre-market:
9.31
0.10
+1.09%
Novavax Inc stock is traded at $9.21, with a volume of 4.42M.
It is up +2.56% in the last 24 hours and up +8.99% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$8.98
Open:
$8.94
24h Volume:
4.42M
Relative Volume:
0.95
Market Cap:
$1.51B
Revenue:
$1.12B
Net Income/Loss:
$440.30M
P/E Ratio:
3.8689
EPS:
2.3805
Net Cash Flow:
$-251.02M
1W Performance:
+1.66%
1M Performance:
+8.99%
6M Performance:
+42.35%
1Y Performance:
+26.34%
1-Day Range:
$8.92
$9.23
1-Week Range:
$8.64
$9.455
52-Week Range:
$6.13
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.21 | 1.48B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
3 Reasons NVAX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Operating margin % of Novavax, Inc. – BSESOF:NVV1 - TradingView
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
NVAX News | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
NVAX Stock Price, Quote & Chart | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Small-Cap Stocks to Avoid: Peloton, Novavax, and BKV Face Financial RisksNews and Statistics - IndexBox
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why (NVAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Assessing Novavax (NVAX) Valuation As Trading Swings Revive Investor Interest - Yahoo Finance
Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus - AD HOC NEWS
Novavax, Inc. Trade Ideas — BOATS:NVAX - TradingView
Novavax Inc stock (US6707721049): vaccine specialist in focus after latest COVID shot update - AD HOC NEWS
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know - Yahoo Finance
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call - Yahoo Finance
Novavax stock (US66987V1098): vaccine maker faces fresh focus after recent company updates - AD HOC NEWS
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda - MSN
Shah Capital Management will vote 'No' across five proposals on Novavax's June 18 ballotSEC filing - marketscreener.com
Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 BallotSEC Filing - TradingView
Shah Capital holds 9% Novavax stake and challenges board (NVAX) - Stock Titan
Shah Capital Management Sent a Presentation to the Board of Novavax, Inc - marketscreener.com
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax stock (US66987V1098): Latest developments and business update - AD HOC NEWS
Novavax targets $230M-$270M 2026 adjusted revenue while refining 2028 opex to $150M-$200M - MSN
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
3 Small-Cap Stocks That Fall Short - The Globe and Mail
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again - MSN
Transcript : Novavax, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
NVAX: Pivot to a platform model and Matrix-M partnerships drive growth, targeting profitability by 2028 - TradingView
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Q1 2026 Novavax Inc Earnings Call Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Vanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAX - MarketBeat
Why Novavax (NVAX) Stock Is Trading Up Today - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Novavax (NVAX) Q1 2026 Earnings Transcript - AOL.com
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know - MSN
Novavax Bets on Turnaround Momentum Following Pfizer Partnership - citybiz
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb - Sahm
Novavax: Betting On This Vaccine Maker's Turnaround Story, After Pfizer Deal - Seeking Alpha
TradingKey - TradingKey
Novavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On ExpectationsWhat's Changed - Yahoo Finance
Best Biotech Stocks To Follow NowMay 11th - MarketBeat
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes - Barchart.com
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again - Stocktwits
Novavax, Inc. (NVAX) is a trending stock: Facts to know before betting on it - MSN
UBS Group AG Has $32.89 Million Stock Position in Novavax, Inc. $NVAX - MarketBeat
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Newton Charles W. | Director |
Apr 25 '26 |
Option Exercise |
0.00 |
9,520 |
0 |
9,520 |
| Shiver John W. | Director |
Mar 10 '26 |
Option Exercise |
0.00 |
7,947 |
0 |
7,947 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):